Physiomics Share Price | |
---|---|
Price | 1.50 |
Bid | 1.40 |
Ask | 1.60 |
Change | 0.00 (0.00%) |
Volume | 73,133 |
Open | 1.50 |
High | 1.50 |
Low | 1.50 |
Prev. Close | 1.50 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.47m |
Market Capitalisation | £2.03m |
Market Size | 30,000 |
52 Week High | 3.15 |
52 Week High Date | 10-May-2023 |
52 Week Low | 0.925 |
52 Week Low Date | 09-Aug-2023 |
# Trades | 2 |
---|---|
Vol. Sold | 40,000 |
Sold Value | £N/A |
Vol. Bought | 33,133 |
Bought Value | £N/A |
PE Ratio | -3.061224 |
Earnings | -0.49 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
26-Apr-24 | 08:46:05 | 1.4415 | 40,000 | Sell* | 1.40 | 1.60 | 576.60 | O Ordinary |
26-Apr-24 | 07:51:40 | 1.57 | 33,133 | Buy* | 1.40 | 1.60 | 520.19 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
25-Jul-23 | 22-Jul-23 | Transfer To | James Simon Millen held the position of Executive Chairman at the time of this trade.James Simon Millen | 0.00 | 500,000 | 1,884,393 | |
18-Jul-23 | 14-Jul-23 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 500,000 | 1,102,723 | |
29-Jun-21 | 28-Jun-21 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 85,715 | 602,723 | |
21-May-21 | 21-May-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 | |
22-Mar-21 | 29-Jan-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 |
Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumourâ„¢ technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.